Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL1313386 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| Ethylene Glycol SCHEMBL5436118 | 0.89 | — | — | |
| SCHEMBL905351 | 0.83 | — | — | |
| SCHEMBL75982 | 0.83 | — | — | |
| Di(Hydroxyethyl)Ether SCHEMBL845987 | 0.80 | TSHR (0.48) | ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL6062827 | 0.78 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL75522 | 0.76 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL6062035 | 0.75 | — | — | |
| SCHEMBL9190940 | 0.74 | LMNA (0.33) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7556956 | 0.74 | LMNA (0.33) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987489-B2 | Method for producing mono-carboxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ether and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | claimed |
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275744-A1 | Method for Producing Mono-Carboxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ether and the Use Thereof | SCO2, HAO2, ACSL3 | SMN1; SMN2 4365/4885LMNA 3557/4885ALDH1A1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.